F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. F-star is the only biotechnology company able to create bispecific antibodies where the second binding site is in the constant Fc region of an antibody (mAb2). Their Modular Antibody Technology™ platform, offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products.

Project Overview

F-star required molecular weight data for a variety of bispecific mAb2 molecules in order to support development decisions. BioPharmaSpec performed on-line Liquid Chromatography with Electrospray-Mass Spectrometric detection (LC/ES-MS, Q-TOF) for a range of mAb2. Depending on the objectives for the study the mAb2 samples were analyzed intact and following (i) reduction, (ii) de-N-glycosylation and (iii) reduction & de-N-glycosylation in separate experiments.

Technical Considerations – Molecular Weight

BioPharmaSpec scientists were instrumental in the conception of the Quadrupole-Time of Flight (Q-TOF) geometry for mass spectrometry, a methodology that allows ultra-high sensitivity sequencing of biopharmaceuticals. We apply this ground-breaking expertise in our laboratories to provide you with accurate and reliable molecular weight data.

Client Testimonial

“We are able to work in a true partnership with BioPharmaSpec, sharing our priorities and objectives to meet our deadlines so that we receive data that enables quality decision making.” ” – Senior Scientist, F-Star Biotechnology Ltd.